Fig. 5

IGF2BP3 promotes the proliferation of bladder cancer cells. A–C GSEA analysis demonstrates a positive correlation between IGF2BP3 mRNA levels and HALLMARKs of "G2M CHECKPOINT" and "MITOTIC SPINDLE" signatures in the TCGA BLCA, GSE31684, and E-MTAB-4321 datasets. D, E Scatterplot showing the mRNA expression correlation between IGF2BP3 and CCNB1/CCNE1 in the TCGA BLCA dataset. F, G Western blot analysis confirming the efficacy of IGF2BP3 overexpression in RT112/84 cells, and silencing by two independent shRNAs in BFTC905 cells. H Western blot analysis of Cyclin B, Cyclin E, CD44, LC-3, and p62 protein levels after IGF2BP3 overexpression in RT112/84 cells and IGF2BP3 knockdown in BFTC905 cells. I, J The effect of IGF2BP3 expression on cell proliferation in RT112/84 cells and IGF2BP3 knockdown in BFTC905 cells was assessed by CCK8 assay. K, L Representative images of colony formation assays in RT112/84 vs. IGF2BP3-OE RT112/84 cells, and BFTC905 vs. IGF2BP3-KD BFTC905 cells, respectively. M, N Flow cytometric analysis of the effect of IGF2BP3 expression on cell cycle distribution in RT112/84 and BFTC905 cells. O Proportions of apoptotic cells. P IGF2BP3 knockdown in BFTC905 inhibited tumor growth in xenograft mice model. The tumor diameter was measured, and tumor volume was calculated every 4 days. Con control, OE overexpression, KD knockdown. **p < 0.01, *p < 0.05